SIRT2‐deficient breast cancer cells exhibit increased acetylation at PKM2 K305, preventing PKM2 tetramerisation and thereby reducing PKM2 enzymatic activity, ultimately altering glucose metabolism and inhibiting tumour growth.246. This evidence concerns the gene SIRT2 and neoplasm.